Skip to main content

Clinical Trials Using Tacrolimus

Review the clinical trials studying tacrolimus on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-43 of 43

211At-BC8-B10 followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Daratumumab and Hyaluronidase-fihj before Standard Desensitization to Lower Donor-Specific Antibodies in Patients Undergoing Donor Bone Marrow or Peripheral Blood Stem Cell Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Orca-T following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody with Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Status: Enrolling by Invitation
Location: 2 locations
Intestinal or Multivisceral Transplantation for the Treatment of Unresectable Mucinous Carcinoma Peritonei, TRANSCAPE Trial
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Venetoclax, Busulfan, Fludarabine, Azacitidine, Decitabine, and Cedazuridine in Treating Patients with High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes Undergoing Donor Stem Cell Transplantation
Status: Temporarily Closed to Accrual
Location: 2 locations
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients with Blood Cancer Undergoing a Donor Stem Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Itacitinib for the Prevention of Graft Versus Host Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Ruxolitinib for Preventing Graft-versus-Host Disease in People with a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Status: Active
Location: 7 locations
Belumosudil for the Prevention of Graft-versus-Host Disease after Donor Hematopoietic Cell Transplant
Status: Active
Location: 7 locations
Cyclophosphamide, Tacrolimus, and Ruxolitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Ruxolitinib with Tacrolimus and Methotrexate for Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid or Lymphoblastic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma or Chronic Myeloid Leukemia
Status: Active
Location: 2 locations
Abatacept in Combination with Mycophenolate Mofetil and Tacrolimus for the Prevention of Graft-versus-Host Disease after Omidubicel Hematopoietic Cell Transplant
Status: Active
Location: Duke University Medical Center, Durham, North Carolina